Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial

Neuroinflammation through the cytokine, tumor necrosis factor-alpha (TNF-α) is thought to play an important role in the pathogenesis of amyotrophic lateral sclerosis (ALS). We conducted a preliminary phase II trial of thalidomide, which reduces levels of TNF-α pre-transcriptionally and post-transcriptionally in vivo and has been shown to prolong disease duration and extend the lifespan of transgenic animal models of ALS. Patients who met diagnostic criteria for ALS received thalidomide at escalating doses to a target dose of 400 mg/day. The primary endpoints in the trial were the ALS Functional Rating Scale (ALSFRS) and pulmonary function testing (PFT) curves after nine months of thalidomide treatment that were compared to historical controls. Secondary endpoints were: survival stratified for newly diagnosed and progressive disease, toxicity, quality of life, and serum cytokine measurements. Twenty-three patients were enrolled, but only 18 were evaluable for the primary outcome. There was no improvement in the ALSFRS or PFT compared to historical controls. Thalidomide had several side-effects in our ALS patients. There was no significant shift in cytokine profile after treatment compared to baseline. In conclusion, treatment of ALS with the TNF-α inhibitor, thalidomide, does not appear to effectively modulate disease progression and can cause adverse effects.

[1]  D. Roberts,et al.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme , 2008, Journal of Neuro-Oncology.

[2]  C. Münch,et al.  Thalidomide causes sinus bradycardia in ALS , 2008, Journal of Neurology.

[3]  R. Chandra,et al.  Elevated Inflammatory Markers in a Group of Amyotrophic Lateral Sclerosis Patients from Northern India , 2008, Neurochemical Research.

[4]  M. Cuccia,et al.  TNF and sTNFR1/2 plasma levels in ALS patients , 2008, Journal of Neuroimmunology.

[5]  R. Michelucci,et al.  Neuropathy in multiple myeloma treated with thalidomide , 2007, Neurology.

[6]  E. Stommel,et al.  Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons , 2007, Neuroscience.

[7]  M. Cudkowicz,et al.  Increased incidence of deep venous thrombosis in ALS , 2007, Neurology.

[8]  A. Rombos,et al.  RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[9]  M. Beal,et al.  Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice , 2006, Journal of the Neurological Sciences.

[10]  J. Julien,et al.  Absence of Tumor Necrosis Factor-α Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutations , 2006, The Journal of Neuroscience.

[11]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.

[12]  J. Kira,et al.  Intrathecal Upregulation of Granulocyte Colony Stimulating Factor and Its Neuroprotective Actions on Motor Neurons in Amyotrophic Lateral Sclerosis , 2006, Journal of neuropathology and experimental neurology.

[13]  L. Defebvre,et al.  Elevated IL-6 and TNF-α levels in patients with ALS: Inflammation or hypoxia? , 2005, Neurology.

[14]  M. Baccarani,et al.  Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma , 2005, European journal of haematology.

[15]  Gian Domenico Borasio,et al.  Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis. , 2004, Journal of palliative medicine.

[16]  P. Bongioanni,et al.  Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. , 2004, The Cochrane database of systematic reviews.

[17]  G. Cavaletti,et al.  Thalidomide sensory neurotoxicity , 2004, Neurology.

[18]  Scott Ferrell,et al.  Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis , 2003, Neurobiology of Disease.

[19]  D. Schoenfeld,et al.  A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis , 2003, Neurology.

[20]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[21]  G. Nicholson,et al.  Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation , 2002, Journal of neurology, neurosurgery, and psychiatry.

[22]  Paul Alan Cox,et al.  Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. , 2002, Neurology.

[23]  G. Sobue,et al.  Differential expression of inflammation‐ and apoptosis‐related genes in spinal cords of a mutant SOD1 transgenic mouse 
model of familial amyotrophic lateral sclerosis , 2002, Journal of neurochemistry.

[24]  D. Schoenfeld,et al.  Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations , 2001, Neurology.

[25]  Robert Kapsa,et al.  Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1 mouse model of amyotrophic lateral sclerosis , 2001, Muscle & nerve.

[26]  J. Elliott.  Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. , 2001, Brain research. Molecular brain research.

[27]  G. Rosoklija,et al.  Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis , 2001, Annals of neurology.

[28]  N. Latov,et al.  Detection of Anti-Gm1 Ganglioside Antibodies in Patients with Neuropathy by a Novel Latex Agglutination Assay , 2000, Journal of immunoassay.

[29]  G. Mora,et al.  Circulating levels of tumour necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis , 2000, Neuroscience Letters.

[30]  A. Hyman,et al.  Tumor Necrosis Factor Induces Hyperphosphorylation of Kinesin Light Chain and Inhibits Kinesin-Mediated Transport of Mitochondria , 2000, The Journal of cell biology.

[31]  P. Stieg,et al.  Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.

[32]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[33]  M. Bellomo,et al.  Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. , 1998, European cytokine network.

[34]  W. Fiers,et al.  The 55-kDa Tumor Necrosis Factor Receptor Induces Clustering of Mitochondria through Its Membrane-proximal Region* , 1998, The Journal of Biological Chemistry.

[35]  J. Niland,et al.  Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases , 1998, Journal of the Neurological Sciences.

[36]  A Hirano,et al.  Neuropathology of ALS , 1996, Neurology.

[37]  D. Schiffer,et al.  Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis , 1996, Journal of the Neurological Sciences.

[38]  S. Sasaki,et al.  Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis , 1996, Neurology.

[39]  Robert H. Brown,et al.  Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice , 1995, Cell.

[40]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[41]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[42]  G. Sobue,et al.  Amyotrophic lateral sclerosis. Lack of central chromatolytic response of motor neurocytons corresponding to active axonal degeneration. , 1983, Archives of neurology.

[43]  Hiroshi Tsukagoshi,et al.  Morphometric quantification of the cervical limb motor cells in controls and in amyotrophic lateral sclerosis , 1979, Journal of the Neurological Sciences.

[44]  M. Sinaki,et al.  Rehabilitation techniques for patients with amyotrophic lateral sclerosis. , 1978, Mayo Clinic proceedings.

[45]  Dong-Kug Choi,et al.  Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis , 2006, The Journal of Neuroscience.

[46]  L. Defebvre,et al.  Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? , 2005, Neurology.

[47]  T. Miyatake,et al.  Morphometry of the degenerative process in the hypoglossal nerves in amyotrophic lateral sclerosis , 2004, Acta Neuropathologica.

[48]  Scott Ferrell,et al.  Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. , 2003, Neurobiology of disease.

[49]  K. Hensley,et al.  Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2002, Journal of neurochemistry.

[50]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. , 1998, Glia.